Literature DB >> 24272680

Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity.

Jasmin Bartl1, Thomas Müller, Edna Grünblatt, Manfred Gerlach, Peter Riederer.   

Abstract

Patients with Parkinson's disease receive selective irreversible monoamine oxidase (MAO)-B inhibitors, but their effects on MAO-A activity are not known during long-term application. We determined MAO-A inhibition in plasma samples from patients with MAO-B inhibitor intake or without MAO-B inhibitor treatment and from healthy controls. We detected a 70 % reduction of MAO-A activity in patients with MAO-B inhibitor therapy in comparison to the other groups. Our results suggest that treatment with MAO-B inhibitor may also influence MAO-A activity in vivo, when administered daily.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24272680     DOI： 10.1007/s00702-013-1120-z

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN： 0300-9564            Impact factor:   3.575


  18 in total

1.  The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.

Authors:  W Birkmayer; P Riederer; M B Youdim; W Linauer
Journal:  J Neural Transm       Date:  1975       Impact factor: 3.575

Review 2.  Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline.

Authors:  Peter Jenner; J William Langston
Journal:  Mov Disord       Date:  2011-09-23       Impact factor: 10.338

Review 3.  Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.

Authors:  Jack J Chen; David M Swope; Khashayar Dashtipour
Journal:  Clin Ther       Date:  2007-09       Impact factor: 3.393

4.  Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain.

Authors:  J Saura; R Kettler; M Da Prada; J G Richards
Journal:  J Neurosci       Date:  1992-05       Impact factor: 6.167

5.  Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine.

Authors:  A R Green; B D Mitchell; A F Tordoff; M B Youdim
Journal:  Br J Pharmacol       Date:  1977-07       Impact factor: 8.739

Review 6.  Type A and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival.

Authors:  Makoto Naoi; Wakako Maruyama; Keiko Inaba-Hasegawa
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

7.  Multiple forms of human brain monoamine oxidase: substrate specificities.

Authors:  G G Collins; M B Youdim
Journal:  Biochem J       Date:  1970-04       Impact factor: 3.857

Review 8.  Recent developments in the regulation of monoamine oxidase form and function: is the current model restricting our understanding of the breadth of contribution of monoamine oxidase to brain [dys]function?

Authors:  Darrell D Mousseau; Glen B Baker
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

Review 9.  Clinical pharmacokinetics and pharmacodynamics of selegiline. An update.

Authors:  I Mahmood
Journal:  Clin Pharmacokinet       Date:  1997-08       Impact factor: 6.447

Review 10.  From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors.

Authors:  Spyros N Deftereos; Evie Dodou; Christos Andronis; Aris Persidis
Journal:  Expert Rev Clin Pharmacol       Date:  2012-07       Impact factor: 5.045
View more
  15 in total

Review 1.  Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.

Authors:  John P M Finberg
Journal:  J Neural Transm (Vienna)       Date:  2018-11-01       Impact factor: 3.575

2.  Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.

Authors:  Torun Malmlöf; Kristin Feltmann; Åsa Konradsson-Geuken; Frank Schneider; Rudolf-Giesbert Alken; Torgny H Svensson; Björn Schilström
Journal:  J Neural Transm (Vienna)       Date:  2014-06-07       Impact factor: 3.575

Review 3.  Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons.

Authors:  Makoto Naoi; Wakako Maruyama; Masayo Shamoto-Nagai
Journal:  J Neural Transm (Vienna)       Date:  2017-12-26       Impact factor: 3.575

Review 4.  Type A monoamine oxidase and serotonin are coordinately involved in depressive disorders: from neurotransmitter imbalance to impaired neurogenesis.

Authors:  Makoto Naoi; Wakako Maruyama; Masayo Shamoto-Nagai
Journal:  J Neural Transm (Vienna)       Date:  2017-03-14       Impact factor: 3.575

5.  Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.

Authors:  Thomas Müller; Peter Riederer; Edna Grünblatt
Journal:  J Neural Transm (Vienna)       Date:  2017-03-15       Impact factor: 3.575

Review 6.  Catechol-O-methyltransferase inhibitors in Parkinson's disease.

Authors:  Thomas Müller
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

Review 7.  Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.

Authors:  Makoto Naoi; Peter Riederer; Wakako Maruyama
Journal:  J Neural Transm (Vienna)       Date:  2015-01-22       Impact factor: 3.575

Review 8.  Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.

Authors:  Paul L McCormack
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

Review 9.  Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.

Authors:  Thomas Müller; Paul Foley
Journal:  Clin Pharmacokinet       Date:  2017-03       Impact factor: 6.447

Review 10.  Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders.

Authors:  David S Goldstein; Irwin J Kopin; Yehonatan Sharabi
Journal:  Pharmacol Ther       Date:  2014-06-16       Impact factor: 12.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.